MicroRNAs and soft tissue sarcomas

Tomohiro Fujiwara, Toshiyuki Kunisada, Ken Takeda, Toshihumi Ozaki

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Soft tissue sarcomas are a highly heterogenous group of malignant tumors that originate from mesenchymal tissues including muscle, adipose and fibrous tissues, blood vessels, and peripheral nerves. A large variety of histological subtypes that current diagnostic approaches recognize present a diagnostic challenge because their clinical and histopathological characteristics are not always distinct. One of the important clinical problems is a lack of useful biomarkers; therefore, the discovery of biomarkers that can be used to detect tumors or predict tumor response to chemotherapy or radiotherapy could help clinicians provide more effective clinical management. Recent reports on microRNAs (miRNAs) in soft tissue sarcomas have provided clues to solve the problem. Evidence for miRNAs in tumor tissues as well as circulating miRNAs in patients’ blood is accelerating the potential to transform clinical applications. In this chapter, we summarize the emerging evidence of dysregulated miRNAs in tumor tissues and patients’ blood and discuss the potential of miRNAs as novel biomarkers and therapeutic targets.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages179-199
Number of pages21
Volume889
DOIs
Publication statusPublished - Jan 1 2015

Publication series

NameAdvances in Experimental Medicine and Biology
Volume889
ISSN (Print)00652598
ISSN (Electronic)22148019

Fingerprint

MicroRNAs
Sarcoma
Tumors
Tissue
Biomarkers
Neoplasms
Blood
Chemotherapy
Peripheral Nerves
Blood vessels
Radiotherapy
Blood Vessels
Adipose Tissue
Muscle
Drug Therapy
Muscles
Therapeutics

Keywords

  • Biomarker
  • MicroRNA
  • Soft tissue sarcoma
  • Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Fujiwara, T., Kunisada, T., Takeda, K., & Ozaki, T. (2015). MicroRNAs and soft tissue sarcomas. In Advances in Experimental Medicine and Biology (Vol. 889, pp. 179-199). (Advances in Experimental Medicine and Biology; Vol. 889). Springer New York LLC. https://doi.org/10.1007/978-3-319-23730-5_10

MicroRNAs and soft tissue sarcomas. / Fujiwara, Tomohiro; Kunisada, Toshiyuki; Takeda, Ken; Ozaki, Toshihumi.

Advances in Experimental Medicine and Biology. Vol. 889 Springer New York LLC, 2015. p. 179-199 (Advances in Experimental Medicine and Biology; Vol. 889).

Research output: Chapter in Book/Report/Conference proceedingChapter

Fujiwara, T, Kunisada, T, Takeda, K & Ozaki, T 2015, MicroRNAs and soft tissue sarcomas. in Advances in Experimental Medicine and Biology. vol. 889, Advances in Experimental Medicine and Biology, vol. 889, Springer New York LLC, pp. 179-199. https://doi.org/10.1007/978-3-319-23730-5_10
Fujiwara T, Kunisada T, Takeda K, Ozaki T. MicroRNAs and soft tissue sarcomas. In Advances in Experimental Medicine and Biology. Vol. 889. Springer New York LLC. 2015. p. 179-199. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-23730-5_10
Fujiwara, Tomohiro ; Kunisada, Toshiyuki ; Takeda, Ken ; Ozaki, Toshihumi. / MicroRNAs and soft tissue sarcomas. Advances in Experimental Medicine and Biology. Vol. 889 Springer New York LLC, 2015. pp. 179-199 (Advances in Experimental Medicine and Biology).
@inbook{3df32be06ed44785844497f30d8fb943,
title = "MicroRNAs and soft tissue sarcomas",
abstract = "Soft tissue sarcomas are a highly heterogenous group of malignant tumors that originate from mesenchymal tissues including muscle, adipose and fibrous tissues, blood vessels, and peripheral nerves. A large variety of histological subtypes that current diagnostic approaches recognize present a diagnostic challenge because their clinical and histopathological characteristics are not always distinct. One of the important clinical problems is a lack of useful biomarkers; therefore, the discovery of biomarkers that can be used to detect tumors or predict tumor response to chemotherapy or radiotherapy could help clinicians provide more effective clinical management. Recent reports on microRNAs (miRNAs) in soft tissue sarcomas have provided clues to solve the problem. Evidence for miRNAs in tumor tissues as well as circulating miRNAs in patients’ blood is accelerating the potential to transform clinical applications. In this chapter, we summarize the emerging evidence of dysregulated miRNAs in tumor tissues and patients’ blood and discuss the potential of miRNAs as novel biomarkers and therapeutic targets.",
keywords = "Biomarker, MicroRNA, Soft tissue sarcoma, Therapeutics",
author = "Tomohiro Fujiwara and Toshiyuki Kunisada and Ken Takeda and Toshihumi Ozaki",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-23730-5_10",
language = "English",
volume = "889",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "179--199",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - MicroRNAs and soft tissue sarcomas

AU - Fujiwara, Tomohiro

AU - Kunisada, Toshiyuki

AU - Takeda, Ken

AU - Ozaki, Toshihumi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Soft tissue sarcomas are a highly heterogenous group of malignant tumors that originate from mesenchymal tissues including muscle, adipose and fibrous tissues, blood vessels, and peripheral nerves. A large variety of histological subtypes that current diagnostic approaches recognize present a diagnostic challenge because their clinical and histopathological characteristics are not always distinct. One of the important clinical problems is a lack of useful biomarkers; therefore, the discovery of biomarkers that can be used to detect tumors or predict tumor response to chemotherapy or radiotherapy could help clinicians provide more effective clinical management. Recent reports on microRNAs (miRNAs) in soft tissue sarcomas have provided clues to solve the problem. Evidence for miRNAs in tumor tissues as well as circulating miRNAs in patients’ blood is accelerating the potential to transform clinical applications. In this chapter, we summarize the emerging evidence of dysregulated miRNAs in tumor tissues and patients’ blood and discuss the potential of miRNAs as novel biomarkers and therapeutic targets.

AB - Soft tissue sarcomas are a highly heterogenous group of malignant tumors that originate from mesenchymal tissues including muscle, adipose and fibrous tissues, blood vessels, and peripheral nerves. A large variety of histological subtypes that current diagnostic approaches recognize present a diagnostic challenge because their clinical and histopathological characteristics are not always distinct. One of the important clinical problems is a lack of useful biomarkers; therefore, the discovery of biomarkers that can be used to detect tumors or predict tumor response to chemotherapy or radiotherapy could help clinicians provide more effective clinical management. Recent reports on microRNAs (miRNAs) in soft tissue sarcomas have provided clues to solve the problem. Evidence for miRNAs in tumor tissues as well as circulating miRNAs in patients’ blood is accelerating the potential to transform clinical applications. In this chapter, we summarize the emerging evidence of dysregulated miRNAs in tumor tissues and patients’ blood and discuss the potential of miRNAs as novel biomarkers and therapeutic targets.

KW - Biomarker

KW - MicroRNA

KW - Soft tissue sarcoma

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84953377153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953377153&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-23730-5_10

DO - 10.1007/978-3-319-23730-5_10

M3 - Chapter

C2 - 26659002

AN - SCOPUS:84953377153

VL - 889

T3 - Advances in Experimental Medicine and Biology

SP - 179

EP - 199

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -